CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Descriptor ID |
D018414
|
MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 5 | 5 |
1995 | 2 | 8 | 10 |
1996 | 3 | 2 | 5 |
1997 | 2 | 2 | 4 |
1998 | 3 | 7 | 10 |
1999 | 3 | 3 | 6 |
2000 | 4 | 9 | 13 |
2001 | 4 | 1 | 5 |
2002 | 7 | 3 | 10 |
2003 | 11 | 11 | 22 |
2004 | 10 | 10 | 20 |
2005 | 18 | 9 | 27 |
2006 | 17 | 9 | 26 |
2007 | 15 | 16 | 31 |
2008 | 13 | 14 | 27 |
2009 | 19 | 11 | 30 |
2010 | 9 | 14 | 23 |
2011 | 15 | 8 | 23 |
2012 | 15 | 14 | 29 |
2013 | 17 | 9 | 26 |
2014 | 15 | 20 | 35 |
2015 | 9 | 9 | 18 |
2016 | 11 | 12 | 23 |
2017 | 17 | 17 | 34 |
2018 | 14 | 21 | 35 |
2019 | 21 | 24 | 45 |
2020 | 17 | 29 | 46 |
2021 | 16 | 30 | 46 |
2022 | 8 | 26 | 34 |
2023 | 2 | 7 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023 05 09; 120(19):e2300706120.
-
Metabolic dysregulation impairs lymphocyte function during severe SARS-CoV-2 infection. Commun Biol. 2023 04 07; 6(1):374.
-
Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study. Eur J Haematol. 2023 Jun; 110(6):732-742.
-
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun. 2023 03 22; 14(1):1566.
-
Linoleic acid potentiates CD8+ T?cell metabolic fitness and antitumor immunity. Cell Metab. 2023 04 04; 35(4):633-650.e9.
-
FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun. 2023 02 10; 14(1):735.
-
Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer. PLoS One. 2023; 18(1):e0279590.
-
Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer. Oncoimmunology. 2023; 12(1):2161167.
-
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of?Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol. 2023 01; 36(1):100028.
-
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022 12 01; 28(23):5030-5039.